Schrodinger (SDGR) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Zymeworks (ZYME) has outperformed Schrodinger (SDGR) over the past year, gaining 60.8% versus a gain of 35.4%. Over five years, ZYME leads with a +2.3% price change compared with -50.7% for SDGR. Schrodinger is the larger company by market cap ($2.04 billion vs $1.90 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SDGR | ZYME |
|---|---|---|
| Share price | $27.29 | $26.53 |
| Market cap | $2.04B | $1.90B |
| 1-day change | -5.57% | +3.43% |
| YTD return | +52.63% | +0.76% |
| 1-year return | +35.37% | +60.79% |
| 5-year return | -50.70% | +2.27% |
| Forward P/E | — | 30.43 |
| EPS (TTM) | $-0.74 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.78 | $31.34 |
| 52-week low | $10.95 | $16.00 |
| Distance from 52-week high | -19.21% | -15.35% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -21.47% | +55.33% |
| Average volume | 1.69M | 673.06K |
| Shares outstanding | 65.64M | 71.20M |
| Employees | 850 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYME has outperformed SDGR by 25.4 percentage points over the past year.
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
SDGR vs ZYME FAQ
Which is bigger, Schrodinger or Zymeworks?
Schrodinger (SDGR) is larger, with a market capitalization of $2.04B compared with $1.90B for Zymeworks (ZYME).
Which stock has performed better over the past year, SDGR or ZYME?
ZYME returned +60.79% over the past 12 months, compared with +35.37% for SDGR (price return, excluding dividends). Past performance does not predict future results.
Are Schrodinger and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.